Vigil Neuroscience price target lowered to $13 from $24 at Wedbush

Wedbush lowered the firm’s price target on Vigil Neuroscience (VIGL) to $13 from $24 and keeps an Outperform rating on the shares. For Vigil, the most important update in the Q4 results was that Phase 2 IGNITE data for iluzanebart in ALSP remains on track to be reported in Q2 2025. The firm continues to assume an accelerated filing path and the earliest potential iluzanebart commercial entry falls in FY27. ALSP unmet need remains high as evidenced by natural history data. Thus, any signs of iluzanebart slowing disease progression would be a positive outcome, Wedbush argues. Admittedly, this represents a crucial readout for Vigil as current cash provides runway into 2026. The firm acknowledges this makes for a challenging setup. Nevertheless, it remains positive on the potential for iluzanebart in IGNITE.